Introduction
The clinician's choice of treatment for gonorrhoea focuses on clinical efficacy, patient acceptability and toxicity. These criteria inevitably encompass consideration of in vitro antimicrobial sensitivities, the pharmacokinetic properties of candidate antimicrobials, anticipated compliance, cost-effectiveness, ease of administration, patient's age, pregnancy and previous adverse drug reactions. Concomitant infection with other sexually transmitted pathogens should be sought and managed appropriately. Department Effective treatment is defined as the elimination of Neisseria gonorrhoeae from all anatomic sites. It also eliminates the potential for continued transmission, minimises complications from the infection, and circumvents the difficulty of ensuring follow-up assessment. An advocated and achievable minimum criterion of clinical efficacy is that treatment for uncomplicated anogenital infection should be demonstrated to eradicate > 95% of infections in sizeable clinical trials.'2 This standard is independent of the prevalence of resistant strains and allows for factors other than resistance that may contribute to treatment failure. Moran and Levine also advocate additional criteria for antimicrobial selection based on the pharmacokinetics of a candidate antimicrobial and its in-vitro sensitivity against prevalent strains of N gonorrhoeae.' Antimicrobial resistance to N gonorrhoeae has shown relentless progression through the acquisition of multiple plasmids and chromosomal mutation. Surveillance data at local, national and international levels are therefore essential to guide the clinician, who often initiates treatment on clinical presentation without prior knowledge of the antimicrobial sensitivity of the N gonorrhoeae in the presenting patient.
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